Kohut Stephen J, Hiranita Takato, Hong Soo-Kyung, Ebbs Aaron L, Tronci Valeria, Green Jennifer, Garcés-Ramírez Linda, Chun Lauren E, Mereu Maddalena, Newman Amy H, Katz Jonathan L, Tanda Gianluigi
Psychobiology, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse/Intramural Research Program/National Institutes of Health/Department of Health and Human Services, Baltimore, Maryland.
Psychobiology, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse/Intramural Research Program/National Institutes of Health/Department of Health and Human Services, Baltimore, Maryland; Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.
Biol Psychiatry. 2014 Nov 15;76(10):802-9. doi: 10.1016/j.biopsych.2014.03.031. Epub 2014 Apr 19.
Subjective effects of cocaine are mediated primarily by dopamine (DA) transporter (DAT) blockade. The present study assessed the hypothesis that different DAT conformational equilibria regulate differences in cocaine-like subjective effects and extracellular DA induced by diverse DA-uptake inhibitors (DUIs).
The relationship between cocaine-like subjective effects and stimulation of mesolimbic DA levels by standard DUIs (cocaine, methylphenidate, WIN35,428) and atypical DUIs (benztropine analogs: AHN1-055, AHN2-005, JHW007) was investigated using cocaine discrimination and DA microdialysis procedures in rats.
All drugs stimulated DA levels with different maxima and time courses. Standard DUIs, which preferentially bind outward-facing DAT conformations, fully substituted for cocaine, consistently producing cocaine-like subjective effects at DA levels of 100-125% over basal values, regardless of dose or pretreatment time. The atypical DUIs, with DAT binding minimally affected by DAT conformation, produced inconsistent cocaine-like subjective effects. Full effects were obtained, if at all, only at a few doses and pretreatment times and at DA levels 600-700% greater than basal values. Importantly, the linear, time-independent, relationship between cocaine-like subjective effects and DA stimulation obtained with standard DUIs was not obtained with the atypical DUIs.
These results suggest a time-related desensitization process underlying the reduced cocaine subjective effects of atypical DUIs that may be differentially induced by the binding modalities identified using molecular approaches. Since the DAT is the target of several drugs for treating neuropsychiatric disorders, such as attention-deficit/hyperactivity disorder, these results help to identify safe and effective medications with minimal cocaine-like subjective effects that contribute to abuse liability.
可卡因的主观效应主要由多巴胺(DA)转运体(DAT)阻断介导。本研究评估了不同DAT构象平衡调节由多种DA摄取抑制剂(DUI)诱导的可卡因样主观效应和细胞外DA差异的假说。
使用大鼠的可卡因辨别和DA微透析程序,研究标准DUI(可卡因、哌甲酯、WIN35,428)和非典型DUI(苯托品类似物:AHN1 - 055、AHN2 - 005、JHW007)的可卡因样主观效应与中脑边缘DA水平刺激之间的关系。
所有药物刺激DA水平的最大值和时间进程不同。优先结合向外的DAT构象的标准DUI完全替代了可卡因,在DA水平比基础值高100 - 125%时,始终产生可卡因样主观效应,无论剂量或预处理时间如何。非典型DUI的DAT结合受DAT构象的影响最小,产生不一致的可卡因样主观效应。如果能产生完全效应,也仅在少数剂量和预处理时间以及DA水平比基础值高600 - 700%时出现。重要的是,非典型DUI未获得标准DUI所呈现的可卡因样主观效应与DA刺激之间的线性、与时间无关的关系。
这些结果表明非典型DUI的可卡因主观效应降低背后存在与时间相关的脱敏过程,这可能由分子方法确定的结合方式差异诱导。由于DAT是治疗神经精神疾病(如注意力缺陷多动障碍)的几种药物的靶点,这些结果有助于识别具有最小可卡因样主观效应且有助于滥用倾向的安全有效药物。